H. Lundbeck A/S
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HLBBF research report →
Price Chart
About the company
H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression.
- CEO
- Charl van Zyl
- IPO
- 2022
- Employees
- 5,214
- HQ
- Valby, CR, DK
Get TickerSpark's AI analysis on HLBBF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $6.94B
- P/E
- 15.14
- Fwd P/E
- 1.82
- PEG
- 2.42
- P/S
- 1.88
- P/B
- 2.17
- EV/EBITDA
- 5.92
- Div Yield
- 1.86%
- Gross Margin
- 77.16%
- Op Margin
- 28.25%
- Net Margin
- 15.52%
- ROE
- 15.32%
- ROIC
- 11.97%
Latest fiscal year · YoY change
- Revenue
- $24.30B+10.4%
- Gross Profit
- $19.33B+8.8%
- Op Income
- $6.33B
- Net Income
- $3.18B+1.3%
- EPS
- $3.21+1.3%
- OCF Growth
- +46.9%
- FCF Growth
- +57.0%
- 52W High
- $9.09
- 52W Low
- $5.70
- 50D MA
- $7.15
- 200D MA
- $6.67
- Beta
- 0.26
- RSI (14)
- 84
- Avg Volume
- 28
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Lundbeck posted strong 9-month growth led by Vyepti and Rexulti, raised full-year guidance, and said it is entering its next “scale” phase with a deeper pipeline and stronger balance sheet.· November 11, 2026
- Revenue reached DKK 20.2 billion, up 13% at constant exchange rates; adjusted EBITDA grew 19%.
- Vyepti remained the fastest-growing anti-CGRP brand, with global revenue of DKK 4.533 billion and 45% constant-currency growth.
- Rexulti revenue reached DKK 5.1 billion, up 13% at constant exchange rates, with AAD still the main growth driver.
- Management raised full-year guidance to 11-12% revenue growth and 15-19% adjusted EBITDA growth.
- Pipeline progress stayed on track, including Japan approval for Vyepti, upcoming bexicasiran data, and Phase III readiness for bucunibart.
Revenue for the first 9 months reached DKK 20.2 billion, up 13% at constant exchange rates, with underlying growth of 11%. Adjusted gross margin was 86.6%. Adjusted EBITDA grew 19%, adjusted EBIT rose 13% to DKK 5.4 billion, net profit increased 30% to GBP 4.1 billion, and adjusted net profit grew 25% to CHF 5.4 billion. Adjusted EPS also grew 25%. For the full year, management raised guidance to 11-12% revenue growth and 15-19% adjusted EBITDA growth, both at constant exchange rates. It also guided to adjusted gross margin of 86-87%, R&D costs of DKK 5.6 billion to DKK 5.7 billion, depreciation and amortization of around DKK 1.9 billion, and an effective tax rate of 21-24%.
Charl van Zyl said Lundbeck has completed the first three years of its focused innovator strategy and is now moving into a “scale” phase, with growth, innovation, and disciplined capital allocation as the core pillars. He emphasized that the company has strengthened its commercial model, pipeline, and balance sheet, and said the quarter confirms the company is in a “very strong position.” His tone was confident and forward-looking, with repeated emphasis on execution and long-term value creation.
Joerg Hornstein said the financial story is that Lundbeck freed up capital, strengthened the balance sheet, and built funding capacity for growth and innovation. He cited revenue of DKK 20.2 billion, adjusted gross margin of 86.6%, adjusted EBITDA up 19%, EBIT up 13% to DKK 5.4 billion, and net debt reduction as evidence of strong cash generation and deleveraging. He also said the lower end of the R&D range versus prior guidance reflects timing, not savings, and that some spend will shift into next year.
Analysts focused on how much of the guidance increase came from R&D phasing, and management said the higher EBITDA outlook is mainly driven by revenue and gross profit, while the lower R&D range is timing-related and should reappear next year. Questions on bexicasiran centered on BID dosing, launch timing, and what to expect in the headline readout; management said the trial supports TID at approval, BID would come post-approval via bridging studies, and the headline release will disclose the primary endpoint and broader efficacy picture. Analysts also pressed on Vyepti’s treatment-line uptake, partner market durability, M&A firepower, and competition for Rexulti and bexicasiran; management said Vyepti’s biggest growth is from moving into second and third line, partner markets are tracking better than expected but remain early, and Lundbeck has about €2 billion to €3 billion of firepower for M&A.
The call showed strong execution in the two main commercial brands, with Vyepti and Rexulti both posting solid constant-currency growth and Vyepti continuing to outgrow the anti-CGRP market. Management also highlighted meaningful pipeline catalysts ahead, including Japan launch for Vyepti, Phase III initiation for bucunibart, and upcoming headline data for bexicasiran. The balance sheet and cash generation appear strong enough to support both R&D investment and potential M&A.
Management acknowledged that partner markets are still new and that it is too early to fully confirm the sustainability of the current demand pattern or the long-term revenue trajectory. The bexicasiran program still faces major binary risk around upcoming trial readouts, with management declining to speculate on detailed data or competition. Rexulti also faces increasing competition and future IRA pricing uncertainty, and management said the exact pricing outcome will not be known until the end of the month.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 33.9%
- Shares Outstanding
- 793.13M
- Float Shares
- 268.92M
Our HLBBF coverage
Recent articles, reports, and earnings notes.
No research on HLBBF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HLBBF report →H. Lundbeck A/S (HLBBF) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 11
H. Lundbeck A/S (HLBBF) Q2 2026 Earnings Call Transcript
seekingalpha.com · Aug 19
H. Lundbeck A/S (HLBBF) Discusses PROCEED Trial Results and Data Presented at AHS on Bokunebart for Headache Treatment Transcript
seekingalpha.com · Jun 5
H. Lundbeck A/S (HLBBF) Shareholder/Analyst Call Transcript
seekingalpha.com · Mar 18
H. Lundbeck A/S (HLBBF) Q4 2025 Earnings Call Transcript
seekingalpha.com · Feb 4
H. Lundbeck Launches Bid for Avadel in Move to Scuttle Alkermes Deal
wsj.com · Nov 14
H. Lundbeck A/S (HLBBF) Q3 2025 Earnings Call Transcript
seekingalpha.com · Nov 12
Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan
prnewswire.com · Mar 10
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.